Market revenue in 2023 | USD 240.7 million |
Market revenue in 2030 | USD 302.5 million |
Growth rate | 3.3% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 63.9% in 2023. Horizon Databook has segmented the Germany pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
It has the lowest survival rate among cancers, with a relative 5-year survival rate of only 10% for both men and women. Risk factors include smoking, obesity, diabetes mellitus type 2, and pancreatitis, highlighting the need for effective early detection and treatment strategies.
Moreover, vaccine trials highlight significant advancements in pancreatic cancer treatment, potentially transforming diagnostic strategies and patient outcomes in this critical medical field. For instance, in April 2024, BioN Tech announced promising 3-year follow-up data from a Phase 1 trial of auto gene cevumeran (BNT122) in resected Pancreatic Ductal Adenocarcinoma (PDAC).
The study showed sustained immune responses in 8 out of 16 patients, correlated with prolonged recurrence-free survival. The mRNA-based cancer vaccine, part of BioN Tech’s iNeST platform, induced de novo T cells targeting neoantigens, with 80% persistence up to 3 years post-treatment.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Germany pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account